189 related articles for article (PubMed ID: 15924763)
1. [Leucovorin rescue after continuing infusion of high dose methotrexate].
Yang LH; Lu XT; Gu J; Hua Y; Zhao WH
Zhonghua Er Ke Za Zhi; 2005 May; 43(5):393-4. PubMed ID: 15924763
[No Abstract] [Full Text] [Related]
2. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.
Widemann BC; Balis FM; Murphy RF; Sorensen JM; Montello MJ; O'Brien M; Adamson PC
J Clin Oncol; 1997 May; 15(5):2125-34. PubMed ID: 9164227
[TBL] [Abstract][Full Text] [Related]
3. [High methotrexate doses in the treatment program for acute lymphoblastic leukemia and lymphosarcoma in children].
Makhonova LA; Maiakova SA; Kiselev AV; Gordina GA; Balakirev SA; Gavrilova IE; Moiseenko EI; Morozova OV
Vopr Onkol; 1990; 36(10):1196-200. PubMed ID: 2251813
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment plasma folate modulates the pharmacodynamic effect of high-dose methotrexate in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma: "folate overrescue" concept revisited.
Sterba J; Dusek L; Demlova R; Valik D
Clin Chem; 2006 Apr; 52(4):692-700. PubMed ID: 16455868
[TBL] [Abstract][Full Text] [Related]
5. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetics of methotrexate in children with acute lymphoblastic leukemia].
Lares-Asseff I; Paredes R; Taboada C; Cravioto J; Velázquez M; Roldán RM; Faisal AG
Bol Med Hosp Infant Mex; 1988 Oct; 45(10):671-80. PubMed ID: 3264171
[No Abstract] [Full Text] [Related]
7. Central nervous system prophylaxis with high-dose methotrexate does not give rise to significant electroencephalographic changes in children with acute lymphoblastic leukemia.
Korinthenberg R; Schneider A; Niemeyer C
J Child Neurol; 2002 Jun; 17(6):409-12. PubMed ID: 12174959
[TBL] [Abstract][Full Text] [Related]
8. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
[TBL] [Abstract][Full Text] [Related]
9. High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how?
Sterba J; Valík D; Bajciová V; Kadlecová V; Gregorová V; Mendelová D
Neoplasma; 2005; 52(6):456-63. PubMed ID: 16284689
[TBL] [Abstract][Full Text] [Related]
10. Nephrotoxicity due to intermediate-dose methotrexate without rescue in an obese adolescent with acute lymphoblastic leukemia.
Sauer M; Rydholm N; Piatkowski J; Lewis V; Steiner M
Pediatr Hematol Oncol; 2002 Mar; 19(2):135-40. PubMed ID: 11881788
[TBL] [Abstract][Full Text] [Related]
11. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia.
Skärby TV; Anderson H; Heldrup J; Kanerva JA; Seidel H; Schmiegelow K;
Leukemia; 2006 Nov; 20(11):1955-62. PubMed ID: 16990760
[TBL] [Abstract][Full Text] [Related]
12. The evaluation of red blood cell folate and methotrexate levels during protocol M in childhood acute lymphoblastic leukemia.
Oosterom N; Fiocco M; Kloos RQH; van der Sluis IM; Pieters R; van Zelst BD; Smith DEC; van den Heuvel-Eibrink MM; de Jonge R; Heil SG
BMC Cancer; 2020 Sep; 20(1):940. PubMed ID: 32998716
[TBL] [Abstract][Full Text] [Related]
13. High-dose methotrexate in acute lymphoblastic leukemia: where is the evidence for its continued use?
Mantadakis E; Cole PD; Kamen BA
Pharmacotherapy; 2005 May; 25(5):748-55. PubMed ID: 15899736
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.
Aumente D; Buelga DS; Lukas JC; Gomez P; Torres A; García MJ
Clin Pharmacokinet; 2006; 45(12):1227-38. PubMed ID: 17112298
[TBL] [Abstract][Full Text] [Related]
15. Oral versus intravenous methotrexate: another opinion.
Kamen BA; Winick N; Holcenberg JS
J Clin Oncol; 1998 Jun; 16(6):2283-5. PubMed ID: 9626235
[No Abstract] [Full Text] [Related]
16. Experience with high dose methotrexate therapy in childhood acute lymphoblastic leukemia in a tertiary care cancer centre of a developing country.
Kapoor G; Sinha R; Abedin S
Pediatr Blood Cancer; 2012 Sep; 59(3):448-53. PubMed ID: 22271707
[TBL] [Abstract][Full Text] [Related]
17. Demyelination and single-carbon transfer pathway metabolites during the treatment of acute lymphoblastic leukemia: CSF studies.
Surtees R; Clelland J; Hann I
J Clin Oncol; 1998 Apr; 16(4):1505-11. PubMed ID: 9552059
[TBL] [Abstract][Full Text] [Related]
18. [Accidental shortening time of high dose methotrexate infusion: case report and literature review].
Charfi R; Salouage I; Trabelsi S; Zarrouk M; Gaïes E; Jebabli N; Meddeb B; Lakhal M; Klouz A
Ann Biol Clin (Paris); 2013; 71(2):219-22. PubMed ID: 23587592
[TBL] [Abstract][Full Text] [Related]
19. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies.
Xu WQ; Zhang LY; Chen XY; Pan BH; Mao JQ; Song H; Li JY; Tang YM
Cancer Chemother Pharmacol; 2014 Jan; 73(1):79-86. PubMed ID: 24158402
[TBL] [Abstract][Full Text] [Related]
20. Myelopathy due to intrathecal chemotherapy: magnetic resonance imaging findings.
Counsel P; Khangure M
Clin Radiol; 2007 Feb; 62(2):172-6. PubMed ID: 17207701
[No Abstract] [Full Text] [Related]
[Next] [New Search]